COVID‐19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: Do the exosomes in convalescent plasma antagonize the weak immune antibodies?

Exosome extracellular vesicles as biologic therapy for COVID‐19 are discussed for two areas. The first involves the growing use of mesenchymal stromal cells (MSCs) for the profound clinical cytokine storm and severe pneumonia in COVID‐19 patients. Instead, it is recommended to treat alternatively wi...

Descripción completa

Detalles Bibliográficos
Autor principal: Askenase, Philip W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Editorial Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710130/
https://www.ncbi.nlm.nih.gov/pubmed/33304473
http://dx.doi.org/10.1002/jev2.12004

Ejemplares similares

Ejemplares similares